Covered recipient · General Payments record
JESSICA BAUMAN
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$3,945.00
3 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,520.00 | 2 |
| Consulting Fee | $1,425.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $2,520.00 | 2 |
| Ares Trading SA | $1,425.00 | 1 |
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JESSICA BAUMAN
NPI 1619139235 · CMS profile ID 579955
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
PHILADELPHIA, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1619139235?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619139235?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619139235?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1619139235?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
3 matching records · $3,945.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–3 of 3.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $630.00 | 11/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142663888 | CMS |
| PFIZER INC. | $1,890.00 | 07/12/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131707098 | CMS |
| Ares Trading SA | $1,425.00 | 03/01/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133237825 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $662,530.20 | 43 |
| PY2024 | Recipient | $4,600.00 | 2 |
| PY2024 | Principal investigator | $597,434.60 | 56 |
| PY2023 | Recipient | $3,200.00 | 1 |
| PY2023 | Principal investigator | $615,260.38 | 77 |
| PY2022 | Principal investigator | $513,473.56 | 47 |
| PY2021 | Principal investigator | $536,056.62 | 88 |
| PY2020 | Recipient | $3,200.00 | 1 |
| PY2020 | Principal investigator | $550,482.65 | 74 |
| PY2019 | Principal investigator | $501,598.41 | 22 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
88 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,131.45 | 12/31/2021 | Non-covered Recipient Entity THE INSTITUTE FOR CANCER RESEARCH | A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib | No dispute reported | 06/30/2026 | 826502373 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,147.48 | 12/31/2021 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer | No dispute reported | 06/30/2026 | 848742799 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $14,141.54 | 12/31/2021 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma R,M cSCC | No dispute reported | 06/30/2026 | 848746449 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $6,599.59 | 12/31/2021 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | No dispute reported | 06/30/2026 | 848746581 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $30,305.08 | 12/31/2021 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 848756405 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $43,369.54 | 12/31/2021 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 848756407 |
| Principal investigator 1 | PFIZER INC. | $10,305.07 | 12/22/2021 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 832578073 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60,629.45 | 12/17/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 860870527 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $7,391.00 | 12/17/2021 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | No dispute reported | 06/30/2026 | 848746579 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $30,116.06 | 12/15/2021 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 848756403 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,877.60 | 12/14/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 860868787 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,877.60 | 12/14/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 860871093 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $758.44 | 12/14/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 860871095 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,207.60 | 12/14/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 860871097 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,005.00 | 12/14/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 860872257 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,731.89 | 12/07/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 860870513 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $758.44 | 11/16/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809491937 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,877.60 | 11/16/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809494989 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,005.00 | 11/16/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809514161 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,207.60 | 11/16/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809535223 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,877.60 | 11/16/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809535271 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,340.00 | 10/27/2021 | Non-covered Recipient Entity Institute For Cancer Research Dba Research Institute Of Fox Chase Cancer Center | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | No dispute reported | 06/30/2026 | 819895331 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $758.44 | 10/15/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809487597 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,207.60 | 10/15/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809487625 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,877.60 | 10/15/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809488017 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,005.00 | 10/15/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809488043 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,877.60 | 10/15/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809488045 |
| Principal investigator 1 | BeiGene, Ltd. | $500.00 | 09/27/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854801 |
| Principal investigator 1 | BeiGene, Ltd. | $2,400.00 | 09/27/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854803 |
| Principal investigator 1 | BeiGene, Ltd. | $4,530.00 | 09/27/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854805 |
| Principal investigator 1 | BeiGene, Ltd. | $1,000.00 | 09/27/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854807 |
| Principal investigator 1 | BeiGene, Ltd. | $1,030.00 | 09/27/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854809 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 09/22/2021 | Non-covered Recipient Entity Institute for Cancer Research | A PHASE 1B 12WEEK OPENLABEL STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF06946860 IN PATIENTS WITH CANCER AND CACHEXIA | No dispute reported | 06/30/2026 | 832803169 |
| Principal investigator 1 | BeiGene, Ltd. | $342.00 | 09/20/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854829 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 09/16/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809490275 |
| Principal investigator 1 | BeiGene, Ltd. | $6,534.00 | 09/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854811 |
| Principal investigator 1 | BeiGene, Ltd. | $5,226.00 | 09/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854813 |
| Principal investigator 1 | BeiGene, Ltd. | $8,777.00 | 09/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854815 |
| Principal investigator 1 | BeiGene, Ltd. | $713.00 | 09/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854817 |
| Principal investigator 1 | BeiGene, Ltd. | $293.00 | 09/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854819 |
| Principal investigator 1 | BeiGene, Ltd. | $168.00 | 09/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854821 |
| Principal investigator 1 | BeiGene, Ltd. | $162.00 | 09/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854823 |
| Principal investigator 1 | BeiGene, Ltd. | $258.00 | 09/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854825 |
| Principal investigator 1 | BeiGene, Ltd. | $197.00 | 09/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854827 |
| Principal investigator 1 | PFIZER INC. | $35,683.49 | 07/21/2021 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 832871971 |
| Principal investigator 1 | PFIZER INC. | $18,520.00 | 06/22/2021 | Non-covered Recipient Entity Institute for Cancer Research | A PHASE 1B 12WEEK OPENLABEL STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF06946860 IN PATIENTS WITH CANCER AND CACHEXIA | No dispute reported | 06/30/2026 | 832692767 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,417.00 | 06/17/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809481441 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,507.50 | 06/17/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809481443 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,316.40 | 06/17/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809481445 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,311.40 | 06/17/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809481741 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,877.60 | 06/17/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809481767 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $758.44 | 06/17/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809481769 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,768.80 | 06/17/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809490345 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $268.00 | 06/17/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809490395 |
| Principal investigator 1 | PFIZER INC. | $236.17 | 05/21/2021 | Covered Recipient Teaching Hospital American Oncologic Hospial | A 6WEEK RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA FOLLOWED BY AN 18WEEK OPENLABEL TREATMENT PERIOD | No dispute reported | 06/30/2026 | 948971421 |
| Principal investigator 1 | BeiGene, Ltd. | $1,829.00 | 05/04/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854775 |
| Principal investigator 1 | BeiGene, Ltd. | $1,494.00 | 05/04/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854777 |
| Principal investigator 1 | BeiGene, Ltd. | $1,688.00 | 05/04/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854791 |
| Principal investigator 1 | BeiGene, Ltd. | $1,494.00 | 05/04/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854797 |
| Principal investigator 1 | Amgen Inc. | $7,901.00 | 04/24/2021 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | AMG 510 Expanded access ex EU (w/LTFU) | No dispute reported | 06/30/2026 | 830979041 |
| Principal investigator 1 | BeiGene, Ltd. | $44.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854767 |
| Principal investigator 1 | BeiGene, Ltd. | $5,226.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854769 |
| Principal investigator 1 | BeiGene, Ltd. | $197.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854771 |
| Principal investigator 1 | BeiGene, Ltd. | $162.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854779 |
| Principal investigator 1 | BeiGene, Ltd. | $147.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854781 |
| Principal investigator 1 | BeiGene, Ltd. | $154.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854783 |
| Principal investigator 1 | BeiGene, Ltd. | $713.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854785 |
| Principal investigator 1 | BeiGene, Ltd. | $293.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854789 |
| Principal investigator 1 | BeiGene, Ltd. | $168.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854793 |
| Principal investigator 1 | BeiGene, Ltd. | $293.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854795 |
| Principal investigator 1 | BeiGene, Ltd. | $258.00 | 04/21/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854799 |
| Principal investigator 1 | BeiGene, Ltd. | $1,944.00 | 04/09/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 855854787 |
| Principal investigator 1 | PFIZER INC. | $18,291.00 | 04/08/2021 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 832872483 |
| Principal investigator 1 | BeiGene, Ltd. | $3,221.00 | 04/05/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients Wi | No dispute reported | 06/30/2026 | 855854765 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,107.40 | 04/01/2021 | Non-covered Recipient Entity Fox Chase Cancer Center | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | No dispute reported | 06/30/2026 | 819894187 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,207.60 | 03/24/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809479837 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $379.22 | 03/24/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809480005 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,417.00 | 03/24/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809480075 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,877.60 | 03/24/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809480255 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,005.00 | 03/24/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809480257 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $268.00 | 03/24/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809483151 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,438.80 | 03/24/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809487265 |
| Principal investigator 1 | Amgen Inc. | $4,930.96 | 03/11/2021 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | AMG 510 Expanded access ex EU (w/LTFU) | No dispute reported | 06/30/2026 | 830979043 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $43,091.15 | 03/10/2021 | Non-covered Recipient Entity THE INSTITUTE FOR CANCER RESEARCH | A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib | No dispute reported | 06/30/2026 | 826478319 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 03/10/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809480077 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 03/10/2021 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 832772541 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $21,385.22 | 02/26/2021 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 809478245 |
| Principal investigator 1 | PFIZER INC. | $17,000.00 | 02/05/2021 | Non-covered Recipient Entity Institute for Cancer Research | A PHASE 1B 12WEEK OPENLABEL STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF06946860 IN PATIENTS WITH CANCER AND CACHEXIA | No dispute reported | 06/30/2026 | 832857121 |